Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma
- 22 April 2023
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 137, 94-101
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast CancerNew England Journal of Medicine, 2008
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialJournal of Clinical Oncology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 1998
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF ReceptorScience, 1985
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985